Gilead’s remdesivir mainly helped healthier Covid-19 patients

The publication also allowed greater insight into which patients seemed to respond best to treatment. The only group to do significantly better on remdesivir were those who were sick enough to need supplemental oxygen, but who weren’t yet on a ventilator or a heart-lung bypass machine. While the lack of benefit might have stemmed from the limited number of patients in those groups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2yp5IGS
via IFTTT